After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.
Blank cheque companies might have disappointed, but options are limited right now for private developers in need of big bucks.
The nightmare on the public markets is not confined to the bigger groups.
The worst half-year period for a decade leaves the biggest medical device companies half a trillion dollars poorer.
A look for winners and losers finds a sector laid low by poor sentiment and Covid fatigue, with Lantheus, Vertex and Jazz providing a few bright spots.